http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3461489-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d3fa61f786878fae97455d646b04b4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01L2224-0231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01L21-568 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01L23-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01L23-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01L24-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06N10-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 |
| filingDate | 2014-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab70c3b5f348900c98daefbeabbfebe3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68e00af077591c7fe839fb7ddb686ace |
| publicationDate | 2019-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3461489-A1 |
| titleOfInvention | Treatment of skin lesions associated with autoimmune and inflammatory diseases using the as2o5 arsenic compound |
| abstract | The invention relates to the field of human autoimmune and / or inflammatory diseases, specifically the use of arsenic compounds for the preparation of medicaments for the treatment and / or prevention of cutaneous lesions associated with autoimmune diseases. -immune and / or inflammatory in a human subject. The subject of the invention is an arsenic compound As 2 O 5 for use in the treatment and / or prevention of cutaneous lesions associated with autoimmune and / or inflammatory diseases in a human subject, a pharmaceutical composition comprising a composed of arsenic As 2 O 5 , preferentially for the treatment and / or prevention of cutaneous lesions associated with autoimmune diseases in a human subject, as well as products containing an As 2 O 5 arsenic compound and an arsenic compound As 2 O 3 as a combination product for simultaneous, separate or spread over time use in the treatment and / or prevention of cutaneous lesions associated with autoimmune diseases in a human subject. |
| priorityDate | 2013-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.